The Janus face of immune stimulation by nanomedicines

Examples for the good and the bad

Julianna Lisziewicz, J. Szebeni

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Nanomedicines are pharmaceutical agents consisting of ∼20-400 nm size particles that overlap with the size of viruses and, hence, are recognized by the immune system. The resulting stimulation of the innate and antigen-specific immune responses can be either beneficial or harmful. This review focuses on two examples of the Janus faced interaction between the nanomedicines and the immune system; the beneficial stimulation of epidermal Langerhans cells and expansion of HIV-specific memory T cells by a therapeutic AIDS vaccine (DermaVir), and the harmful triggering of the complement (C) system leading to hypersensitivity reactions, called C activation related pseudoallergy (CARPA). In addition to the illustrated survey of the molecular-cellular interactions underlying these phenomena, this review provides an update on the clinical development of DermaVir and the state of CARPA prevention - anti-CARPA therapy.

Original languageEnglish
Pages (from-to)13-18
Number of pages6
JournalEuropean Journal of Nanomedicine
Volume3
Issue number1
DOIs
Publication statusPublished - May 2010

Fingerprint

Nanomedicine
Medical nanotechnology
Janus
stimulation
immune systems
Immune System
Immune system
Chemical activation
activation
AIDS Vaccines
Langerhans Cells
Histocompatibility Antigens Class II
Particle Size
acquired immunodeficiency syndrome
vaccines
Hypersensitivity
human immunodeficiency virus
Vaccines
T-cells
HIV

Keywords

  • Anaphylaxis
  • Dendritic cells
  • First-line HIV therapy
  • Hypersensitivity reactions
  • Immune toxicity
  • Immunotherapy
  • Infusion reactions
  • Nanoparticles
  • Vaccine

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Physical and Theoretical Chemistry
  • Biomedical Engineering

Cite this

The Janus face of immune stimulation by nanomedicines : Examples for the good and the bad. / Lisziewicz, Julianna; Szebeni, J.

In: European Journal of Nanomedicine, Vol. 3, No. 1, 05.2010, p. 13-18.

Research output: Contribution to journalArticle

@article{bf97393fd6494438b5b93e58f5f114a2,
title = "The Janus face of immune stimulation by nanomedicines: Examples for the good and the bad",
abstract = "Nanomedicines are pharmaceutical agents consisting of ∼20-400 nm size particles that overlap with the size of viruses and, hence, are recognized by the immune system. The resulting stimulation of the innate and antigen-specific immune responses can be either beneficial or harmful. This review focuses on two examples of the Janus faced interaction between the nanomedicines and the immune system; the beneficial stimulation of epidermal Langerhans cells and expansion of HIV-specific memory T cells by a therapeutic AIDS vaccine (DermaVir), and the harmful triggering of the complement (C) system leading to hypersensitivity reactions, called C activation related pseudoallergy (CARPA). In addition to the illustrated survey of the molecular-cellular interactions underlying these phenomena, this review provides an update on the clinical development of DermaVir and the state of CARPA prevention - anti-CARPA therapy.",
keywords = "Anaphylaxis, Dendritic cells, First-line HIV therapy, Hypersensitivity reactions, Immune toxicity, Immunotherapy, Infusion reactions, Nanoparticles, Vaccine",
author = "Julianna Lisziewicz and J. Szebeni",
year = "2010",
month = "5",
doi = "10.3884/0003.1.5",
language = "English",
volume = "3",
pages = "13--18",
journal = "European Journal of Nanomedicine",
issn = "1662-5986",
publisher = "Walter de Gruyter GmbH",
number = "1",

}

TY - JOUR

T1 - The Janus face of immune stimulation by nanomedicines

T2 - Examples for the good and the bad

AU - Lisziewicz, Julianna

AU - Szebeni, J.

PY - 2010/5

Y1 - 2010/5

N2 - Nanomedicines are pharmaceutical agents consisting of ∼20-400 nm size particles that overlap with the size of viruses and, hence, are recognized by the immune system. The resulting stimulation of the innate and antigen-specific immune responses can be either beneficial or harmful. This review focuses on two examples of the Janus faced interaction between the nanomedicines and the immune system; the beneficial stimulation of epidermal Langerhans cells and expansion of HIV-specific memory T cells by a therapeutic AIDS vaccine (DermaVir), and the harmful triggering of the complement (C) system leading to hypersensitivity reactions, called C activation related pseudoallergy (CARPA). In addition to the illustrated survey of the molecular-cellular interactions underlying these phenomena, this review provides an update on the clinical development of DermaVir and the state of CARPA prevention - anti-CARPA therapy.

AB - Nanomedicines are pharmaceutical agents consisting of ∼20-400 nm size particles that overlap with the size of viruses and, hence, are recognized by the immune system. The resulting stimulation of the innate and antigen-specific immune responses can be either beneficial or harmful. This review focuses on two examples of the Janus faced interaction between the nanomedicines and the immune system; the beneficial stimulation of epidermal Langerhans cells and expansion of HIV-specific memory T cells by a therapeutic AIDS vaccine (DermaVir), and the harmful triggering of the complement (C) system leading to hypersensitivity reactions, called C activation related pseudoallergy (CARPA). In addition to the illustrated survey of the molecular-cellular interactions underlying these phenomena, this review provides an update on the clinical development of DermaVir and the state of CARPA prevention - anti-CARPA therapy.

KW - Anaphylaxis

KW - Dendritic cells

KW - First-line HIV therapy

KW - Hypersensitivity reactions

KW - Immune toxicity

KW - Immunotherapy

KW - Infusion reactions

KW - Nanoparticles

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=79954556479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954556479&partnerID=8YFLogxK

U2 - 10.3884/0003.1.5

DO - 10.3884/0003.1.5

M3 - Article

VL - 3

SP - 13

EP - 18

JO - European Journal of Nanomedicine

JF - European Journal of Nanomedicine

SN - 1662-5986

IS - 1

ER -